Alnylam Pharmaceuticals, Inc. vs NextEra Energy, Inc. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.66 (market cap $29.60B), while NextEra Energy, Inc. trades at $85.83 (market cap $178.85B). The key difference: NextEra Energy, Inc. is far larger — about 6× Alnylam Pharmaceuticals, Inc.'s market cap, and NextEra Energy, Inc. pays a 2.91% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | NEE | |
|---|---|---|
Market Cap | $29.60B | $178.85B |
Sector | Health | Utilities |
52-Week High | $491.22 | $97.88 |
52-Week Low | $205.48 | $69.77 |
Enterprise Value | $27.56B | $286.18B |
Dividend Yield | — | 2.91% |
Trailing returns across standard periods
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →NextEra Energy's regulated utility, Florida Power & Light, distributes power to more than 5 million customers in Florida. FP&L contributes more than 60% of the group's operating earnings. The renewable energy segment generates and sells power throughout the United States and Canada. Consolidated generation capacity totals more than 50 gigawatts and includes natural gas, nuclear, wind, and solar assets.
Read more on NEE →